Antares Pharma takes back needle-free rights:
This article was originally published in Clinica
Executive Summary
Antares Pharma has reacquired the US rights to its needle-free injector technology that were bought exclusively by Bio-Technology General in December 1999 for the administration of growth hormones. The Exton, Pennsylvania company says it will now seek other partners that could achieve a level of success similar to that achieved by Ferring Pharmaceuticals, its partner in Europe.